期刊文献+

抗BLyS抗体抑制BLyS诱导小鼠脾细胞增殖实验方法的优化

Development of Anti-BLyS Antibody Neutralization Assay for BLyS-induced Splenocyte Proliferation
下载PDF
导出
摘要 目的:建立BLyS抗体抑制BLyS作用下小鼠脾细胞增殖实验的方法。方法:首先通过DOE全因子实验验证BLyS能抑制脾淋巴细胞增殖后的凋亡,初步确定BLyS和刺激因子LPS的使用浓度、细胞密度及培养天数。然后进一步优化BLyS、Belimumab和LPS的使用浓度、孵育方式、培养天数等条件,确定抗体抑制BLyS作用下小鼠脾细胞增殖实验的方法。结果:BLyS能抑制小鼠脾淋巴细胞增殖后的凋亡;Belimumab对BLyS作用下小鼠脾细胞的增殖有显著中和作用。结论:建立BLyS抗体抑制BLyS作用下小鼠脾细胞增殖实验的方法,为进一步研究人BLyS与自身免疫疾病治疗药物奠定了基础。 Objectives: Establishing a method to detect the neutralization on BLyS-induced splenocyte proliferation. Methods: Design of experiment determine the initial concentration of BLyS, cell density and stimulation time. stimulation such as concentration of LPS, cell density and stimulation effect of anti-BLyS antibody (DOE) has been applied to Once the conditions of LPS time were determined, the concentrations of BLyS and Belimumab were optimized. Thereafter, the incubation time of Belimumab/BLyS were measured. Results: BLyS effectively inhibited the apoptosis of mouse splenocytes stimulated by LPS; Belimumab had a significant neutralization effect on BLyS-induced mouse splenocyte proliferation. Conclusion: It has been successfully established a method of measuring the inhibitory effect of anti-BLyS antibody against BLyS-induced splenocyte proliferation. It warrants future development of therapies for autoimmune diseases through inhibition of BLyS.
出处 《药学与临床研究》 2013年第1期29-32,共4页 Pharmaceutical and Clinical Research
关键词 B淋巴细胞刺激因子 BELIMUMAB 脂多糖 脾淋巴细胞 自身免疫疾病 BLyS Belimumab LPS Splenic lymphocyte Autoimmune disease
  • 相关文献

参考文献13

  • 1Bossen C,Schneider P. BAFF, APRIL and their recep- tors: structure, function and signaling [J]. Semin lm- munol, 2006, 18(5): 263-75.
  • 2Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens[J]. J Leukoc Biol, 1999, 65(5): 680-3.
  • 3Woodland RT, Sehmidt MR, Thompson CB, el al. BLyS and B cell homeostasis[J]. Semin Immunol, 2006, 18(5): 318-26.
  • 4Baker KP. BLyS--an essential survival factor for B cells: basic biology, links to pathology and therapeutic target[J]. A utoimmun Rev, 2004, 3(5): 368-75.
  • 5Tieng AT, Peeva E. B-cell-directed therapies in sys- temic lupus erythematosus [J]. Semin Arthritis Rheum, 2008, 38(3): 218-27.
  • 6Zhang J, Roschke V, Baker KP, et al. Cutting edge: arole for B lymphocyte stimulator in systemic lupus ery- thematosus[J]. J lmmunol, 2001, 166(1): 6-10.
  • 7Liu Z, Davidson A. BAFF inhibition: a new class of drugs for the treatment of autoimmunity [J]. Exp Cell Res, 2011, 317(9): 1270-7.
  • 8Sun J, Lin Z, Feng J, et al. BAFF-targeting therapy, a promising strategy for treating autoimmune diseases[J]. Eur J Pharmacol, 2008, 597(1-3): 1-5.
  • 9Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B- cell autoimmune disease [J]. Nature, 2000, 404(6781): 995-9.
  • 10Liu Z, Davidson A. BAFF and selection of autoreac- tire B cells[J]. Trends lmmunol, 2011, 32(8): 388-94.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部